Bulk Quote Inquiry

GPC-HM131-100μg / Inquiry

GPC-HM131-500μg / Inquiry

GPC-HM131-1mg / Inquiry

Human GPC3/Glypican 3 Protein

Product Info

Recombinant Human GPC3/Glypican 3 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Gln25-His559.[Accession | P51654]

Molecular Weight

The protein has a predicted MW of 61.6 kDa. Due to glycosylation, the protein migrates to 42 kDa, 70-115 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

Human GPC3 on Tris-Bis PAGE under reduced condition. The purity is greater than 90%.


The purity of Human GPC3 is greater than 95% as determined by SEC-HPLC.


Immobilized Human GPC3, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-GPC3 Ab.,hFc Tag with the EC50 of 11.7ng/ml determined by ELISA.

Batch to Batch Consistency

Immobilized Human GPC3, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-GPC3 Ab.,hFc Tag with the EC50 of 11.7/11.3/14.3ng/ml determined by ELISA.


Glypican-3 is a protein ,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed.


glypican proteoglycan 3; glypican-3; GPC3; DGSX; Glypican 3; GTR2-2; heparan sulphate proteoglycan; Intestinal protein OCI-5; MXR7; OCI5; OCI-5; secreted glypican-3; SGB; SGBS; SGBS1SDYS


(1)Ho M , Kim H . Glypican-3: A new target for cancer immunotherapy[J]. European Journal of Cancer, 2011, 47(3):0-338.

Kactus Biosystems Co.Ltd
Online Message